Heres how they work and why they matter: Renal Disease: Targeting Fibrosis and Inflammation TB4 fragments, particularly Ac-SDKP, demonstrate potent anti-fibrotic and anti-inflammatory effects in chronic kidney disease (CKD)
Exercise 1 Choose the Correct Medication Fill in the blank
For weight loss, GLP-1 has been shown to support significant reductions in body weight when combined with lifestyle changes like diet and exercise
The cardiovascular safety profiles of GLP-1RAs are favorable, with no significant increase in the incidence of acute pancreatitis or pancreatic cancer reported.14 However, their use is associated with a higher frequency of gastrointestinal adverse events, such as nausea, vomiting, and diarrhea.15 GLP-1RAs are considered safe in patients with chronic kidney disease and effective in reducing the risk of severe hypoglycemia.16 In individuals with established cardiovascular diseases, GLP-1RAs have been shown to significantly lower the risk of major adverse cardiovascular events.15 Nevertheless, limited cardiovascular and renal outcome data for certain agents, such as oral semaglutide, have constrained their broader clinical application.17 In the context of post-transplant diabetes, GLP-1RAs exhibit efficacy and safety profiles comparable to those observed in non-transplant populations.18 This review was conducted through comprehensive searches of electronic databases, including Web of Science and PubMed, using a full-text search strategy
Long-Term Safety Questions and Research Gaps Limited Clinical Data Most clinical trials last 12 years
